Clinical trial
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade…
NCT00113360 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00113360 |
|---|---|
| Title | RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma |
| Official title | Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroendocrine Carcinoma, Islet Cell Carcinoma |
| Intervention type | Drug |
| Interventions | RAD001, Octreotide Depot |
| Enrollment | 67 |
| Start date | Jan 1, 2005 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Jun 8, 2005 |
| Last update posted | May 1, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: